Taxol Articles
Xenova reports positive Ph II data for XR9576
15 May 2001
Enzon's PEG-paclitaxel now in Phase I
10 May 2001
Ontogen begins Phase I trial of OC144-093
8 May 2001
IM862 potential in combined cancer therapy?
8 May 2001
IVAX offering up to $500M in senior notes
1 May 2001
B-MS 1st-qtr pharma sales up 8% at $3.7B
26 April 2001
Boston's coronary stent trials halted in Europe
26 April 2001
NaPro wins milestone in US paclitaxel program
25 April 2001
IVAX Corp boosted by court decision
23 April 2001
Euro NSCLC market sees renewed growth
21 March 2001
Cook to start trials of paclitaxel stent in USA
15 March 2001
NaPro, Abbott file for generic Taxol in USA
8 March 2001
Asta licenses BioNumerik cancer drug
28 February 2001
Bristol-Myers Squibb's "solid year" sees net earnings rise 13%
25 January 2001
Combined CV787 and Taxotere for advanced prostate cancer
24 January 2001
NaPro's paclitaxel approved in Israel
11 January 2001
Concern over UK cancer drug provision
4 December 2000
NeoTherapeutics expands into oncology with new subsidiary
30 November 2000
IVAX' dispels generic Taxol delay report
17 November 2000
Fast-track review for Isis
15 November 2000
AstraZeneca reveals new oncology data
10 November 2000
B-MS drops paclitaxel lawsuit against IVAX
25 October 2000
B-MS net earnings increase 13%
23 October 2000
IVAX clears the way for paclitaxel launch
6 October 2000
Slight reprieve for B-MS over generic Taxol
4 October 2000
B-MS focuses on intense growth and reveals product pipeline
2 October 2000
More bad news for B-MS over Taxol
22 September 2000
B-MS buying back $2 billion in shares
22 September 2000
Cell Therapeutics looking to raise $119M
22 September 2000
IVAX gains final approval for Taxol - update
21 September 2000
Stock Commentary New York
21 September 2000
IVAX gains final approval for Taxol
18 September 2000
IVAX wins backing of US appellate court in Taxol patent dispute
14 September 2000
Stock Commentary New York
14 September 2000
Angiotech trial of paclitaxel in MS extended
14 September 2000
More twists and turns in generic Taxol dispute - UPDATE
13 September 2000
AstraZeneca launches Losec follow-up Nexium in the UK
12 September 2000
More twists and turns in generic Taxol dispute
11 September 2000
Stock Commentary New York
7 September 2000
Stock Commentary New York
31 August 2000
IVAX wavers on paclitaxel speculation
10 August 2000
Stock Commentary New York
10 August 2000
B-MS up on strong sales of Glucophage
24 July 2000
FDA OKs new regimen for cancer drug Taxol
11 July 2000
Dr Reddy's launches Irnocam in India
7 July 2000
S-P's Caelyx backed for ovarian cancer in EU
5 July 2000
NICE ok's taxane use in breast cancer
16 June 2000
Quebec cancer patients "denied new drugs"
13 June 2000
Isis sees 85% response in ISIS 3521 trial
24 May 2000
Protarga's DHA-linked taxane shows promise
24 May 2000
CTI gains arsenic trioxide priority review
18 May 2000
UK NICE probes taxane guidance speculation
18 April 2000
Stock Commentary New York
13 April 2000
NICE dismisses taxane clearance speculation
12 April 2000
BioNumerik gets fast-track status for BNP7787
16 March 2000
Big sales boost for reformulated drugs
13 March 2000
Stock Commentary New York
9 March 2000
B-MS will hit earnings goal, despite Taxol blow
7 March 2000
B-MS Taxol patents under fire in USA
2 March 2000
B-MS sees delay in Taxol patent case
17 February 2000
TLC suffers as FDA requests more data
4 February 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
Recent developments in drug delivery - by Mark Greener
19 January 2000
Genentech begins pivotal trial of RhuMAb-VEGF
4 January 2000
Genentech boosted on asthma data, BLA 2000
21 December 1999
R-PR gets FDA panel OK for Taxotere use
15 December 1999
Vertex Pharmaceuticals' Incel, Phase II data
24 November 1999
Swiss major Novartis Pharma pulls out of Isis cancer drug deal
23 November 1999
Guilford sees progress across R&D programs
4 November 1999
B-MS' Taxol wins FDA OK for early breast cancer
28 October 1999
B-MS, Otsuka link up on new antipsychotic
22 September 1999
Mixed fortunes for companies from latest ODAC deliberations
21 September 1999
B-MS' Taxol improves survival in breast cancer
6 August 1999
Ivax launches Paxene in Czech Republic, files PLA
3 August 1999
Abbott and NaPro sign paclitaxel deal
29 July 1999
IVAX's Paxene cleared in Europe
27 July 1999
Magainin's Locilex "not approvable"
27 July 1999
Ethyol approved for dry mouth in USA
1 July 1999
Squalamine enters Phase II for NSCLC
25 June 1999
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
